Literature DB >> 23328910

Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer.

Diederik M Somford1, Caroline M Hoeks, Christina A Hulsbergen-van de Kaa, Thomas Hambrock, Jurgen J Fütterer, J Alfred Witjes, Chris H Bangma, Henk Vergunst, Geert A Smits, Jorg R Oddens, Inge M van Oort, Jelle O Barentsz.   

Abstract

PURPOSE: We aimed to determine whether diffusion-weighted magnetic resonance imaging, by means of the apparent diffusion coefficient (ADC), is able to guide magnetic resonance-guided biopsy in patients fit for active surveillance (AS) and identify patients harboring high-grade Gleason components not suitable for AS.
MATERIALS AND METHODS: Our study was approved by the institutional review board of all participating hospitals, and all patients signed informed consent at inclusion. Fifty-four consecutive patients with low-risk prostate cancer (PCa) underwent multiparametric magnetic resonance imaging (MP-MRI) at inclusion for AS. Cancer-suspicious regions (CSRs) upon 3-T MP-MRI were identified in all patients, and magnetic resonance-guided biopsy was performed in all CSRs to obtain histopathological verification. For all CSRs, a median ADC (mADC) was calculated. Wilcoxon signed ranks and Mann-Whitney tests was performed to detect differences between the groups. We used the area under the receiver operating characteristic curve to evaluate the accuracy of mADC to predict the presence of PCa in a CSR. Level of statistical significance was set at P < 0.05.
RESULTS: Mean mADC in the CSRs with PCa was 1.04 × 10⁻³ mm²/s (SD, 0.29), whereas the CSRs with no PCa displayed a mean mADC of 1.26 × 10⁻³ mm²/s (SD, 0.25; P < 0.001). Cancer-suspicious regions with a high-grade Gleason component displayed a mean mADC of 0.84 × 10⁻³ mm²/s (SD, 0.35) vs a mean mADC for the low-grade CSRs of 1.09 × 10⁻³ mm²/s (SD, 0.25; P < 0.05). A diagnostic accuracy of mADC for predicting the presence of PCa in a CSR with an area under the receiver operating characteristic curve of 0.73 was established (95% confidence interval, 0.61-0.84).
CONCLUSIONS: Median ADC is able to predict the presence and grade of PCa in CSRs identified by MP-MRI.

Entities:  

Mesh:

Year:  2013        PMID: 23328910     DOI: 10.1097/RLI.0b013e31827b711e

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  24 in total

1.  Diffusion-weighted MRI of the prostate: advantages of Zoomed EPI with parallel-transmit-accelerated 2D-selective excitation imaging.

Authors:  Kolja M Thierfelder; Michael K Scherr; Mike Notohamiprodjo; Jakob Weiß; Olaf Dietrich; Ullrich G Mueller-Lisse; Josef Pfeuffer; Konstantin Nikolaou; Daniel Theisen
Journal:  Eur Radiol       Date:  2014-08-27       Impact factor: 5.315

2.  Computed diffusion-weighted imaging of the prostate at 3 T: impact on image quality and tumour detection.

Authors:  Andrew B Rosenkrantz; Hersh Chandarana; Nicole Hindman; Fang-Ming Deng; James S Babb; Samir S Taneja; Christian Geppert
Journal:  Eur Radiol       Date:  2013-06-12       Impact factor: 5.315

3.  A comparison of two methods for estimating DCE-MRI parameters via individual and cohort based AIFs in prostate cancer: a step towards practical implementation.

Authors:  Andriy Fedorov; Jacob Fluckiger; Gregory D Ayers; Xia Li; Sandeep N Gupta; Clare Tempany; Robert Mulkern; Thomas E Yankeelov; Fiona M Fennessy
Journal:  Magn Reson Imaging       Date:  2014-01-21       Impact factor: 2.546

4.  Diffusion-weighted magnetic resonance imaging for prediction of insignificant prostate cancer in potential candidates for active surveillance.

Authors:  Tae Heon Kim; Jae Yong Jeong; Sin Woo Lee; Chan Kyo Kim; Byung Kwan Park; Hyun Hwan Sung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Hyun Moo Lee; Han Yong Choi; Seong Soo Jeon
Journal:  Eur Radiol       Date:  2015-01-31       Impact factor: 5.315

Review 5.  The role of radiomics in prostate cancer radiotherapy.

Authors:  Rodrigo Delgadillo; John C Ford; Matthew C Abramowitz; Alan Dal Pra; Alan Pollack; Radka Stoyanova
Journal:  Strahlenther Onkol       Date:  2020-08-21       Impact factor: 3.621

6.  Diagnostic performance of apparent diffusion coefficient parameters for glioma grading.

Authors:  Qun Wang; JiaShu Zhang; Xinghua Xu; XiaoLei Chen; BaiNan Xu
Journal:  J Neurooncol       Date:  2018-03-24       Impact factor: 4.130

7.  Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?

Authors:  Jim C Hu; Edward Chang; Shyam Natarajan; Daniel J Margolis; Malu Macairan; Patricia Lieu; Jiaoti Huang; Geoffrey Sonn; Frederick J Dorey; Leonard S Marks
Journal:  J Urol       Date:  2014-02-08       Impact factor: 7.450

Review 8.  The expanding landscape of diffusion-weighted MRI in prostate cancer.

Authors:  Andreas G Wibmer; Evis Sala; Hedvig Hricak; Hebert Alberto Vargas
Journal:  Abdom Radiol (NY)       Date:  2016-05

9.  Dynamic contrast-enhanced MRI of the prostate with high spatiotemporal resolution using compressed sensing, parallel imaging, and continuous golden-angle radial sampling: preliminary experience.

Authors:  Andrew B Rosenkrantz; Christian Geppert; Robert Grimm; Tobias K Block; Christian Glielmi; Li Feng; Ricardo Otazo; Justin M Ream; Melanie Moccaldi Romolo; Samir S Taneja; Daniel K Sodickson; Hersh Chandarana
Journal:  J Magn Reson Imaging       Date:  2014-05-16       Impact factor: 4.813

Review 10.  Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancer.

Authors:  Seyed Saeid Dianat; H Ballentine Carter; Katarzyna J Macura
Journal:  Urol Oncol       Date:  2013-06-17       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.